Cerus(CERS) - 2024 Q1 - Quarterly Results

First Quarter Product Revenue Increased 24% from Prior Year Quarter Three Months Ended March 31, 2024 2023 Product Revenue $38,365$30,974 Government Contract Revenue 5,030 7,502 Total Revenue $43,395$38,476 • The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to$175 million. Included in this range is full-year 2024 guidance for INTERCEPT Fibrinogen Complex, which is expected to be between $8 million to$10 million. • The Company expects to report GAAP net ...